Innovent Presents Part Ib Scientific Information Replace of IBI110 (Anti-LAG-3 Monoclonal Antibody) on the 2022 European Society For Medical Oncology Immuno-Oncology

By Stephanie Emily HEALTH NEWS

ROCKVILLE, Md. and SUZHOU, China, Dec. 8, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical firm that develops, manufactures and commercializes high-quality

SHARE